AlphAIAlphAI — Financial news for AI agents
BenzingaJUN 164 min read$OMH

This Sarepta Therapeutics Analyst Turns Bearish; Here Are Top 5 Downgrades For Monday - Angi (NASDAQ:ANGI), Ohmyhome (NASDAQ:OMH)

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings page.

Original reporting
Benzinga · Avi Kapoor
Published Jun 16, 2025, 1:47 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jun 16, 2025, 2:01 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
This Sarepta Therapeutics Analyst Turns Bearish; Here Are Top 5 Downgrades For Monday - Angi (NASDAQ:ANGI), Ohmyhome (NASDAQ:OMH) — source image
Source · www.benzinga.com
Decision brief

The 30-second read

$OMHNeutralMed
01

Why it matters

The upgrade of ANGIV suggests positive momentum, while downgrades elsewhere indicate caution. Overall market impact is moderate.

02

Market read

The news primarily affects biotech stocks, especially ANGIV and SRPT, with limited impact on other sectors.

03

What to watch

Potential upcoming clinical trial results or regulatory decisions that could significantly impact these stocks.

Timing: Short-term (next 1-2 weeks)

Background

Recent analyst downgrades and upgrades reflect evolving market perceptions of these companies, especially in the biotech sector.

Company-level read

Ticker impact

$OMHNeutralMedium confidence
Context

Low relevance due to neutral sentiment and small impact from analyst downgrade.

Expected impact

No significant price movement expected in the short term.

Evidence & confidence

The neutral sentiment and low relevance score suggest limited influence on OMH's stock price.

$SRPTBullishMedium confidence
Context

Moderate relevance; somewhat-bullish sentiment indicates potential upward movement.

Expected impact

Possible slight upward movement; monitor technical levels.

Evidence & confidence

The mixed sentiment suggests cautious optimism, but technical analysis should guide timing.

Market effects

Sector

Potential positive sentiment in the biotech and healthcare sectors due to ANGIV's upgrade.

Regional

Limited; primarily US-based stocks affected.

Global

Low; news pertains mainly to US equities and sector-specific developments.

Counterpoint

What could challenge this read

Some analysts may view the downgrade of Sarepta as a sign of underlying issues, cautioning against overconfidence in the bullish sentiment.

Key entities

  • Company
    Sarepta Therapeutics

    Biotech firm specializing in neuromuscular disease treatments.

  • Stock Ticker
    ANGIV

    NASDAQ listed biotech stock with recent positive analyst sentiment.

  • Stock Ticker
    OMH

    Ohmyhome, a real estate platform, with neutral analyst outlook.

  • Stock Ticker
    PRO

    ProShares, a financial services company, with neutral outlook.

  • Stock Ticker
    PKG

    Packaging Corporation of America, with neutral sentiment.

Read at source← All news

Related articles

SEP 8
$SRPTMed

Jefferies reiterates Sarepta Therapeutics stock rating on trial data outlook

Jefferies reiterated a Buy rating and $30.00 price target for Sarepta Therapeutics (SRPT), citing potential 40% upside. The firm expects Phase I/II trial data in 2H 2026, with competitive results potentially driving significant stock movement. SRPT reported Q2 2026 earnings beating estimates, with EPS of $0.64 vs. $0.22 forecasted and revenue of $401.3M vs. $383M expected. Mizuho also reiterated an Outperform rating with a $31.00 target.

investing.com2 min
SEP 8
$SRPTHighAI 8/10

A Rivals Clinical Stumble Sends Sarepta Therapeutics Stock Lower - Sarepta Therapeutics (NASDAQ:SRPT)

Sarepta Therapeutics (SRPT) stock fell 8.09% after Novartis (NVS) reported Phase 3 trial results for del-desiran in myotonic dystrophy type 1 (DM1) that did not meet primary endpoints. Sarepta is developing SRP-1003 for DM1, with Phase 1/2 data expected in late 2026. The company noted positive early data and potential for optimized dosing. SRPT is above short-term moving averages but below the 200-day SMA, indicating mixed signals.

benzinga.com2 min
SEP 8
$SRPTMedAI 8/10

Mizuho reiterates Sarepta stock rating after Novartis trial miss

Mizuho reiterated an Outperform rating and $31.00 price target on Sarepta Therapeutics (SRPT), stating the sell-off after Novartis' failed trial is excessive. The firm noted that Novartis' del-desiran showed clinical activity in secondary endpoints, which may aid Sarepta's SRP-1003 development. SRPT stock fell 10% following the news but remains up 35% over six months. The company recently reported Q2 2026 earnings of $0.64 per share, exceeding estimates, with revenue at $401.3 million.

uk.investing.com2 min
SEP 8
$SRPTHighAI 8/10

Why is Sarepta Therapeutics stock sliding today?

Sarepta Therapeutics (SRPT) stock fell 7.6% in pre-market trading after Novartis' (NVS) Phase III trial failure for a neuromuscular disease treatment, impacting investor confidence in the therapeutic class. Several other pharmaceutical stocks, including AMGN, LLY, IONS, and DYN, also declined. Sarepta faces additional challenges with tightened 2026 revenue guidance and regulatory uncertainty. The broader market's risk-off tone amplified the sell-off, with SRPT trading at $20.80, below its 52-wee

investing.com2 min